A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
Top Cited Papers
Open Access
- 12 December 2019
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 134 (24), 2127-2138
- https://doi.org/10.1182/blood.2019001869
Abstract
In a Plenary Paper, Young et al describe impressive favorable outcomes of emicizumab prophylaxis in children with hemophilia A and factor VIII inhibitors, reporKeywords
This publication has 33 references indexed in Scilit:
- Guidelines for the management of hemophiliaHaemophilia, 2012
- How to manage invasive procedures in children with haemophiliaBritish Journal of Haematology, 2012
- A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A managementJournal of Thrombosis and Haemostasis, 2012
- The principal results of the International Immune Tolerance Study: a randomized dose comparisonBlood, 2012
- Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with InhibitorsNew England Journal of Medicine, 2011
- Paediatric haemophilia with inhibitors: existing management options, treatment gaps and unmet needsHaemophilia, 2009
- Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitorsJournal of Thrombosis and Haemostasis, 2007
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort studyBlood, 2007
- The Haemo‐QoL Index: developing a short measure for health‐related quality of life assessment in children and adolescents with haemophiliaHaemophilia, 2006